Ginkgo Bioworks Holdings (DNA) Share-based Compensation (2020 - 2026)

Ginkgo Bioworks Holdings has reported Share-based Compensation for 7 years, with the latest figure at $15.9 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 8.82% year-over-year to $15.9 million; the trailing twelve-month figure through Mar 2026 stood at $77.5 million (down 14.06% YoY), and the FY2025 full-year result was $81.5 million, down 27.41% from the prior year.
• Share-based Compensation for Q1 2026 stood at $15.9 million, down from $21.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $652.8 million in Q1 2022, with the low at $14.0 million in Q3 2024.
• Historically, Share-based Compensation has averaged $139.5 million across 5 years, with a median of $40.8 million in 2024.
• The largest YoY upside for Share-based Compensation was 553138.14% in 2022 against a maximum downside of 93.2% in 2022.
• Ginkgo Bioworks Holdings' Share-based Compensation stood at $108.2 million in 2022, then tumbled by 60.4% to $42.8 million in 2023, then plunged by 52.0% to $20.6 million in 2024, then grew by 2.27% to $21.0 million in 2025, then fell by 24.61% to $15.9 million in 2026.
• The last three Share-based Compensation figures came in at $15.9 million (Q1 2026), $21.0 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.